These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 21563652)
1. Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models. Borbath I; Stärkel P Acta Gastroenterol Belg; 2011 Mar; 74(1):34-44. PubMed ID: 21563652 [TBL] [Abstract][Full Text] [Related]
2. The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats. Schneider-Merck T; Borbath I; Charette N; De Saeger C; Abarca J; Leclercq I; Horsmans Y; Stärkel P Eur J Cancer; 2009 Jul; 45(11):2050-60. PubMed ID: 19427195 [TBL] [Abstract][Full Text] [Related]
3. Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis. Stärkel P; Charette N; Borbath I; Schneider-Merck T; De Saeger C; Abarca J; Leclercq I; Horsmans Y Mol Carcinog; 2012 Oct; 51(10):816-25. PubMed ID: 21882255 [TBL] [Abstract][Full Text] [Related]
4. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats. Reif S; Weis B; Aeed H; Gana-Weis M; Zaidel L; Avni Y; Romanelli RG; Pinzani M; Kloog Y; Bruck R J Hepatol; 1999 Dec; 31(6):1053-61. PubMed ID: 10604579 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. Borbath I; Leclercq IA; Sempoux C; Abarca-Quinones J; Desaeger C; Horsmans Y Chem Biol Interact; 2010 Jan; 183(1):238-48. PubMed ID: 19874807 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotide. Borbath I; Leclercq IA; Abarca-Quinones J; Desaeger C; Lebrun V; Moulin P; Sempoux C; Horsmans Y Cancer Sci; 2007 Dec; 98(12):1831-9. PubMed ID: 17900309 [TBL] [Abstract][Full Text] [Related]
7. Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives. Wu L; Pang Y; Qin G; Xi G; Wu S; Wang X; Chen T PLoS One; 2017; 12(2):e0171840. PubMed ID: 28182780 [TBL] [Abstract][Full Text] [Related]
8. The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. Borbath I; Leclercq I; Moulin P; Sempoux C; Horsmans Y Eur J Cancer; 2007 Jul; 43(11):1755-63. PubMed ID: 17582756 [TBL] [Abstract][Full Text] [Related]
9. The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid. Khwaja A; Sharpe CC; Noor M; Kloog Y; Hendry BM Kidney Int; 2005 Aug; 68(2):474-86. PubMed ID: 16014024 [TBL] [Abstract][Full Text] [Related]
10. Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. Li S; Ghoshal S; Sojoodi M; Arora G; Masia R; Erstad DJ; Lanuti M; Hoshida Y; Baumert TF; Tanabe KK; Fuchs BC J Gastrointest Surg; 2019 Jan; 23(1):101-111. PubMed ID: 30367397 [TBL] [Abstract][Full Text] [Related]
12. Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. Yu J; Shen B; Chu ES; Teoh N; Cheung KF; Wu CW; Wang S; Lam CN; Feng H; Zhao J; Cheng AS; To KF; Chan HL; Sung JJ Hepatology; 2010 Jun; 51(6):2008-19. PubMed ID: 20512989 [TBL] [Abstract][Full Text] [Related]
13. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Schiffer E; Housset C; Cacheux W; Wendum D; Desbois-Mouthon C; Rey C; Clergue F; Poupon R; Barbu V; Rosmorduc O Hepatology; 2005 Feb; 41(2):307-14. PubMed ID: 15660382 [TBL] [Abstract][Full Text] [Related]
14. Single-cell RNA sequencing reveals the mechanism of sonodynamic therapy combined with a RAS inhibitor in the setting of hepatocellular carcinoma. Wu B; Yuan Y; Liu J; Shang H; Dong J; Liang X; Wang D; Chen Y; Wang C; Zhou Y; Jing H; Cheng W J Nanobiotechnology; 2021 Jun; 19(1):177. PubMed ID: 34118951 [TBL] [Abstract][Full Text] [Related]
15. Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. DePeralta DK; Wei L; Ghoshal S; Schmidt B; Lauwers GY; Lanuti M; Chung RT; Tanabe KK; Fuchs BC Cancer; 2016 Apr; 122(8):1216-27. PubMed ID: 26914713 [TBL] [Abstract][Full Text] [Related]
16. Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc. Yaari-Stark S; Shaked M; Nevo-Caspi Y; Jacob-Hircsh J; Shamir R; Rechavi G; Kloog Y Int J Cancer; 2010 May; 126(10):2268-81. PubMed ID: 19998334 [TBL] [Abstract][Full Text] [Related]
17. Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid. Reif S; Aeed H; Shilo Y; Reich R; Kloog Y; Kweon YO; Bruck R J Hepatol; 2004 Aug; 41(2):235-41. PubMed ID: 15288472 [TBL] [Abstract][Full Text] [Related]
18. Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice. Nasr M; Selima E; Hamed O; Kazem A Eur J Pharmacol; 2014 Jan; 723():267-75. PubMed ID: 24291100 [TBL] [Abstract][Full Text] [Related]
19. [Induction of necrosis in the hepatocellular carcinoma HepG2 xenografts treated with SOM230]. Xie Y; Chen S; Wang CH; Tang CW Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):759-64. PubMed ID: 19874692 [TBL] [Abstract][Full Text] [Related]